US Pharma MarketingThe post Italy’s WISE raises $34.8m in Series D to advance spinal cord stimulator development appeared first on Medical Device Network.
Italy’s WISE raises $34.8m in Series D to advance spinal cord stimulator development
WISE's SCS has been designed to deliver targeted, directional stimulation through a minimally invasive percutaneous implant technique. WISE's Heron lead has been designed to deliver targeted, directional stimulation through a minimally invasive percutaneous implant technique. SCS represents one of the fastest-growing segments within the broader neurology devices market. Credit: sasirin pamai / Shutterstock.com WISE has raised €30m ($34.8m) to advance the development of its spinal cord stimulation (SCS) device for chronic pain treatment. The final close of the Italian company’s oversubscribed Series D financing round saw participation from ENEA Tech and Biomedical, along with existing investors. Alongside Biomedical’s capital commitment,…
WISE's SCS has been designed to deliver targeted, directional stimulation through a minimally invasive percutaneous implant technique.
Source: Medical Device Network